Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3863-3872

  Natsume, Akito ^a   In, Mika ^a   Takamura, Hiroyuki ^a   Nakagawa, Tomoaki ^a   Shimizu, Yukiko ^a   Kitajima, Kazuko ^a   Wakitani, Masako ^a   Ohta, So ^a   Satoh, Mitsuo ^a   Shitara, Kenya ^a   Niwa, Rinpei ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; CD52 ANTIGEN; CHIMERIC ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; PROTEIN A; RITUXIMAB; CARBOHYDRATE; CD20 ANTIGEN; GLYCOPROTEIN; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CHO CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; CONTROLLED STUDY; DAUDI CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN STRUCTURE; LEUKEMIA CELL LINE; LYMPHOCYTE DEPLETION; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAJI CELL; ANIMAL; CHEMISTRY; CRICETULUS; CYTOLOGY; HAMSTER; METHODOLOGY; MONONUCLEAR CELL; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, NEOPLASM; CARBOHYDRATES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; LEUKOCYTES, MONONUCLEAR; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY;

EID: 45549090117     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6297     Document Type: Article

References (50)

1. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
2. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8.
3. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7.
4. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-8.
5. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
6. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
7. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
8. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001;276:6591-604.
9. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005-10.
10. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999;17:176-80.
11. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-40.
12. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
13. Miyoshi E, Uozumi N, Noda K, Hayashi N, Hori M, Taniguchi N. Expression of α1-6 fucosyltransferase in rat tissues and human cancer cell lines. Int J Cancer 1997; 72:1117-21.
14. Niwa R, Hatanaka S, Shoji-Hosaka E, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcγRIIIa functional polymorphism. Clin Cancer Res 2004;10:6248-55.
15. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004;64:2127-33.
16. 297-linked oligosaccharides. J Immunol Methods 2005;306:151-60.
17. Natsume A, Wakitani M, Yamane-Ohnuki N, et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods 2005;306:93-103.
18. Shoji-Hosaka E, Kobayashi Y, Wakitani M, et al. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem 2006;140:777-83.
19. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004;87:614-22.
20. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001;166:2571-5.
21. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 2006;177:1129-38.
22. Michaelsen TE, Aase A, Westby C, Sandlie I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand J Immunol 1990;32:517-28.
23. Brekke OH, Bremnes B, Sandin R, Aase A, Michaelsen TE, Sandlie I. Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis. Mol Immunol 1993;30: 1419-25.
24. Schumaker VN, Calcott MA, Spiegelberg HL, Muller-Eberhard HJ. Ultracentrifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 1976;15: 5175-81.
25. Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61.
26. Lutz R, Michael C, Herman W, Greg W. Reshaping human antibodies for therapy. Nature 1988;332:323-7.
27. Zuckier LS, Chang CJ, Scharff MD, Morrison SL. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res 1998;58:3905-8.
28. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991;173:1025-8.
29. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991;173: 1483-91.
30. Tan LK, Shopes RJ, Oi VT, Morrison SL. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A 1990;87: 162-6.
31. Norderhaug L, Brekke OH, Bremnes B, et al. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge. Eur J Immunol 1991;21:2379-84.
32. Urlaub G, Mitchell PJ, Kas E, et al. Effect of γ rays at the dihydrofolate reductase locus: deletions and inversions. Somat Cell Mol Genet 1986;12:555-66.
33. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11:2327-36.
34. Kabat EA, Wu TT, Perry H, Gottesman K, Foeller C. Sequences of proteins of immunological interest. 5th ed. NIH Publication No. 91-3242. Bethesda (MD): NIH; 1991.
35. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
36. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol 1992;87: 105-10.
37. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476-83.
38. Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000;49:259-66.
39. Jefferis R, Lund J, Mizutani H, et al. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 1990;268: 529-37.
40. Cobo-Ibanez T, Martin-Mola E. Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. Expert Opin Pharmacother 2007;8:1373-97.
41. Liu CM, McKenna JK, Krueger GG. Alefacept: a novel biologic in the treatment of psoriasis. Drugs Today 2004; 40:961-74.
42. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000;164: 4178-84.
43. Gaboriaud C, Juanhuix J, Gruez A, et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 2003;278:46974-82.
44. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996;9:617-21.
45. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 1981; 20:2361-70.
46. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 1997;158:2211-7.
47. Kim JK, Firan M, Radu CG, et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999;29:2819-25.
48. Roopenian1 DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25.
49. Masuda K, Kubota T, Kaneko E, et al. Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 2007;44:3122-31.
50. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.